Seattle Genetics Inc., of Bothell, Wash., reported that sales of its lymphoma therapy, Adcetris (brentuximab vedotin), hit $83.7 million in the fourth quarter, up 18 percent from net sales of $70.8 million in the fourth quarter of 2016. Read More
Akcea Therapeutics Inc., of Cambridge, Mass., said it completed enrollment in a phase IIb study of AKCEA-APO(a)-LRx in patients with high Lp(a) and established cardiovascular disease to determine the dose level and frequency of administration for a planned phase III cardiovascular outcome study and to determine the safety and tolerability profile of the antisense drug. Read More
Viking Therapeutics Inc., of San Diego, announced the closing of its underwritten public offering of about 12.7 million shares of common stock for gross proceeds of about $63.3 million, with underwriters exercising their full option to buy additional shares. Read More
HONG KONG – As a part of China's development plan for the Guangdong-Hong Kong-Macau Greater Bay Area, the Hong Kong Polytechnic University (PolyU) and its allies from the city cluster have established collaborations with U.S. institutions in the field of biotech research and translational medicine. Read More
LONDON – New research has pinpointed asparagine as a key factor in promoting the formation of metastases in breast cancer and suggests a probable mechanism for how the bioavailability of a single amino acid enables tumor cells to colonize secondary sites. Read More
Nearly 35 years after Hatch-Waxman cleared the way for a robust generics industry, the U.S. is still waiting for lightning to strike twice, this time with biosimilars. Read More
Having taken in the data from the phase IIa Action study with Tysabri (natalizumab) by Biogen Inc., investors weren't too surprised by results from the phase IIb, dose-ranging Action 2 experiment in acute ischemic stroke (AIS) that turned up no improvement compared to placebo. Read More
Gilead Sciences Inc. reported that fourth-quarter sales of its hepatitis C virus (HCV) therapies halved since last year, falling to $1.5 billion from $3.2 billion in the fourth quarter of 2016 as new competition arrived on the scene and fewer patients started treatment. Read More
